Sarepta Therapeutics (NASDAQ:SRPT) Stock Price Up 8.2% – Time to Buy?

Sarepta Therapeutics, Inc. (NASDAQ:SRPT)’s stock price was up 8.2% during trading on Tuesday. The company traded as high as $19.05 and last traded at $19.1810. 982,982 shares changed hands during mid-day trading, a decline of 68% from the average daily volume of 3,087,907 shares. The stock had previously closed at $17.73.

Analyst Ratings Changes

A number of brokerages have weighed in on SRPT. Needham & Company LLC reaffirmed an “underperform” rating on shares of Sarepta Therapeutics in a report on Monday, September 28th. Wolfe Research raised Sarepta Therapeutics from a “peer perform” rating to an “outperform” rating and set a $27.00 price target for the company in a report on Thursday, July 9th. Zacks Research downgraded Sarepta Therapeutics from a “hold” rating to a “strong sell” rating in a research note on Monday, October 5th. Wall Street Zen lowered Sarepta Therapeutics from a “buy” rating to a “hold” rating in a report on Saturday, August 8th. Finally, HC Wainwright reiterated a “sell” rating and issued a $5.00 price objective on shares of Sarepta Therapeutics in a research report on Monday, October 5th. Seven investment analysts have rated the stock with a Buy rating, six have issued a Hold rating and eight have given a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Reduce” and a consensus price target of $22.59.

Sarepta Therapeutics Stock Up 9.5%

The firm has a 50 day moving average of $19.30 and a two-hundred day moving average of $18.68. The stock has a market capitalization of $2.05 billion, a PE ratio of -6.71, a P/E/G ratio of 0.31 and a beta of 0.38. The company has a current ratio of 4.42, a quick ratio of 2.62 and a debt-to-equity ratio of 0.55.

Sarepta Therapeutics (NASDAQ:SRPT) last posted its earnings results on Wednesday, August 5th. The biotechnology company reported $0.64 EPS for the quarter, topping analysts’ consensus estimates of $0.22 by $0.42. The company had revenue of $401.25 million for the quarter, compared to the consensus estimate of $366.39 million. Sarepta Therapeutics had a negative return on equity of 1.60% and a negative net margin of 13.48%. Sarepta Therapeutics’s quarterly revenue was down 34.3% compared to the same quarter last year. During the same period in the previous year, the business earned $2.02 earnings per share. Equities research analysts anticipate that Sarepta Therapeutics, Inc. will post 3.27 earnings per share for the current year.

Institutional Investors Weigh In On Sarepta Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. Meeder Asset Management Inc. acquired a new stake in Sarepta Therapeutics in the 2nd quarter valued at about $27,000. Nykredit A S acquired a new position in Sarepta Therapeutics during the second quarter worth about $43,000. Ancora Advisors LLC acquired a new position in Sarepta Therapeutics during the second quarter worth about $45,000. Allworth Financial LP acquired a new position in Sarepta Therapeutics during the second quarter worth about $58,000. Finally, Rockefeller Capital Management L.P. lifted its holdings in shares of Sarepta Therapeutics by 98.3% in the fourth quarter. Rockefeller Capital Management L.P. now owns 4,104 shares of the biotechnology company’s stock valued at $88,000 after purchasing an additional 2,034 shares in the last quarter. 86.68% of the stock is currently owned by hedge funds and other institutional investors.

Sarepta Therapeutics Company Profile

Sarepta Therapeutics, Inc (NASDAQ: SRPT) is a biotechnology company focused on developing and commercializing precision genetic medicines for rare diseases. Its research programs include RNA-based therapies, gene therapy and other genetic medicine approaches designed to address the underlying causes of serious genetic disorders.

The company’s primary commercial focus has been Duchenne muscular dystrophy (DMD). Sarepta markets Exondys 51, Vyondys 53 and Amondys 45, exon-skipping therapies for certain patients with DMD mutations, as well as Elevidys, a gene therapy for eligible patients with Duchenne muscular dystrophy.